Latest Utilities News

Service Stream is set to broaden its industrial services reach through the acquisition of Queensland’s RIE Group, a specialist in high-voltage electrical and instrumentation services. The deal enhances Service Stream’s market presence in key energy sectors amid ongoing contract wins.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

Service Stream has locked in $455 million worth of new contracts, including a $405 million nine-year deal with Yarra Valley Water and $50 million in power station outage works in Queensland, boosting its infrastructure services footprint.

Klevo Rewards is pursuing an Australian Credit Licence acquisition to enable crypto-centric credit products for Fly Wallet users, aiming to reduce declined transactions and boost platform utility.

Gentrack Group delivered steady revenue with a 12% rise in recurring income but saw EBITDA fall due to project delays and investment. The company announced two acquisitions to bolster AI and energy pricing capabilities alongside a $20 million share buyback plan.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Xenitra Limited's OPAL Real World Asset tokenised sales ecosystem has generated over $500,000 in sales within its first month, onboarding more than 130 distributors and positioning the company as an early mover in blockchain-enabled FMCG sales in China.

Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.

Pacific Edge has raised NZ$25.4 million through an oversubscribed placement priced at NZ$0.17 per share, aiming to bolster operations, support Medicare re-coverage efforts, and advance its bladder cancer diagnostic tests.

The Asian Development Bank ramped up its commitments to $29.3 billion in 2025, driving private sector growth, regional cooperation, and climate resilience across Asia and the Pacific.

EMVision is broadening its emu™ Pivotal Trial to include acute ischaemia detection, aiming to accelerate FDA clearance and enhance the brain scanner's clinical impact. Recruitment has passed 125 patients across US and Australian sites, with full enrolment expected by early 2027.